Embolotherapy in the Management of Hepatocellular Carcinoma

ABSTRACT

Hepatocellular carcinoma (HCC) ranks fifth in frequency of cancers worldwide. The incidence of HCC in the United States is rising, primarily due to the number of patients who were infected by hepatitis in the 1960s and 1970s coupled with the rising migrant population from Asia, where hepatitis is widely prevalent. Up to 80% of the patients present with multicentric HCC and advanced liver disease or comorbidities that restrict the option of resection or liver transplantation. The dual blood supply (arterial and portal) to the liver with predominantly arterial supply to the tumor has made embolotherapy a cornerstone in the management of inoperable HCC. The techniques have become refined not only due to the development of microcatheter angiographic capabilities, but also in the ability to deliver a wide variety of therapeutic agents to these tumors. This article reviews the fundamental principles of bland embolization, chemoembolization, and radioembolization in the management of HCC.

Embolization - hepatocellular carcinoma - chemoembolization - radioembolization

REFERENCES

• 1 Blum H E. Hepatocellular carcinoma: therapy and prevention.  World J Gastroenterol. 2005;  11(47) 7391-7400
• 2 Tanaka Y, Hanada K, Mizokami M et al.. Inaugural Article: A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades.  Proc Natl Acad Sci U S A. 2002;  99(24) 15584-15589
• 3 Del Pozo A C, López P. Management of hepatocellular carcinoma.  Clin Liver Dis. 2007;  11(2) 305-321
• 4 Befeler A S. Chemoembolization and bland embolization: a critical appraisal.  Clin Liver Dis. 2005;  9(2) 287-300 , vii
• 5 Kulik L M. Advancements in hepatocellular carcinoma.  Curr Opin Gastroenterol. 2007;  23(3) 268-274
• 6 Okuda K, Ohtsuki T, Obata H et al.. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients.  Cancer. 1985;  56(4) 918-928
• 7 Zhu A X. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.  Cancer. 2008;  112(2) 250-259
• 8 Covey A M, Maluccio M A, Schubert J et al.. Particle embolization of recurrent hepatocellular carcinoma after hepatectomy.  Cancer. 2006;  106(10) 2181-2189
• 9 Brown K T. Fatal pulmonary complications after arterial embolization with 40–120- micro m tris-acryl gelatin microspheres.  J Vasc Interv Radiol. 2004;  15(2 Pt 1) 197-200
• 10 Izaki K, Sugimoto K, Sugimura K, Hirota S. Transcatheter arterial embolization for advanced tumor thrombus with marked arterioportal or arteriovenous shunt complicating hepatocellular carcinoma.  Radiat Med. 2004;  22(3) 155-162
• 11 Lopez P M, Villanueva A, Llovet J M. Systematic review: evidence-based management of hepatocellular carcinoma–an updated analysis of randomized controlled trials.  Aliment Pharmacol Ther. 2006;  23(11) 1535-1547
• 12 Cammà C, Schepis F, Orlando A et al.. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.  Radiology. 2002;  224(1) 47-54
• 13 Llovet J M, Real M, Montaña X et al.. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial.  Lancet. 2002;  359(9319) 1734-1739
• 14 Lo C M, Ngan H, Tso W K et al.. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma.  Hepatology. 2002;  35(5) 1164-1171
• 15 Stuart K. Chemoembolization in the management of liver tumors.  Oncologist. 2003;  8(5) 425-437
• 16 Ensminger W D, Gyves J W. Clinical pharmacology of hepatic arterial chemotherapy.  Semin Oncol. 1983;  10(2) 176-182
• 17 Lewis A L, Gonzalez M V, Lloyd A W et al.. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization.  J Vasc Interv Radiol. 2006;  17(2 Pt 1) 335-342
• 18 Qian J, Truebenbach J, Graepler F et al.. Application of poly-lactide-co-glycolide-microspheres in the transarterial chemoembolization in an animal model of hepatocellular carcinoma.  World J Gastroenterol. 2003;  9(1) 94-98
• 19 Poon R T, Tso W K, Pang R W et al.. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.  Clin Gastroenterol Hepatol. 2007;  5(9) 1100-1108
• 20 Constantin M, Fundueanu G, Bortolotti F et al.. Preparation and characterisation of poly(vinyl alcohol)/cyclodextrin microspheres as matrix for inclusion and separation of drugs.  Int J Pharm. 2004;  285(1–2) 87-96
• 21 Murthy R, Nunez R, Szklaruk J et al.. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications.  Radiographics. 2005;  25(Suppl 1) S41-S55
• 22 Kennedy A, Nag S, Salem R et al.. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium.  Int J Radiat Oncol Biol Phys. 2007;  68(1) 13-23
• 23 Kulik L M, Atassi B, van Holsbeeck L et al.. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation.  J Surg Oncol. 2006;  94(7) 572-586
• 24 Sangro B, Bilbao J I, Boan J et al.. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma.  Int J Radiat Oncol Biol Phys. 2006;  66(3) 792-800
• 25 Ibrahim S M, Lewandowski R J, Sato K T et al.. Radioembolization for the treatment of unresectable hepatocellular carcinoma: a clinical review.  World J Gastroenterol. 2008;  14(11) 1664-1669